Patent 7244448 was granted and assigned to Tekmira Pharmaceuticals Corporation on July, 2007 by the United States Patent and Trademark Office.
This invention relates to liposomal antineoplastic agents (e.g., camptothecin) compositions and methods of using such compositions for treating neoplasia and for inhibiting angiogenesis. The compositions and methods are useful for modulating the plasma circulation half-life of an active agent.